Valuation: Petros Pharmaceuticals, Inc.

Market Cap 131K 119K 110K 99.05K 187K 12.23M 194K 1.32M 523K 6.6M 491K 481K 20.86M P/E 2024
-0.12x
P/E 2025 -0.01x
Enterprise Value -5.01M -4.54M -4.2M -3.79M -7.15M -468M -7.42M -50.58M -20.01M -252M -18.78M -18.39M -797M EV / Sales 2024
1.49x
EV / Sales 2025 -
Free-Float
74.41%
Yield 2024 *
-
Yield 2025 -
1 day-13.79%
1 week+57.48%
Current month+150.00%
1 month+85.19%
3 months+85.19%
6 months-27.30%
Current year-37.11%
1 week 0
Extreme 0.0025
0
1 month 0
Extreme 0.001825
0
Current year 0
Extreme 0.001825
0.01
1 year 0
Extreme 0.0017
0.02
3 years 0
Extreme 0.0017
56.75
5 years 0
Extreme 0.0017
1,300
10 years 0
Extreme 0.0017
1,489.98
Manager TitleAgeSince
Director of Finance/CFO 66 -
President 49 30/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
05/06/26 Free

Director

1,875,000 4.4251%
02/01/26 Free

Director

500,000 1.1800%
02/01/26 Free

Chairperson

500,000 1.1800%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+57.48%-66.67%-99.98% 131K
-0.66%-4.37%+21.09%+47.25% 254B
-1.80%-4.38%+2.42%+8.66% 159B
-1.65%-4.34%-21.25%+41.03% 149B
-1.51%-3.74%-57.71%-20.81% 62.37B
-1.57%+1.37%+24.42%+57.59% 60.62B
+0.73%+0.07%+4.76%-12.90% 53.05B
-0.40%-3.18%+19.17%+52.21% 48.55B
-3.63%-5.61%+4.12%+63.37% 46.7B
-0.80%-5.41%+19.00%+71.75% 44.21B
Average -2.51%-2.12%-5.07%+20.82% 88B
Weighted average by Cap. -1.23%-2.99%+3.05%+33.82%

Financials

2024 2025
Net sales 5.11M 4.64M 4.29M 3.87M 7.3M 478M 7.58M 51.66M 20.43M 258M 19.18M 18.78M 814M -
Net income -14.32M -13M -12.01M -10.83M -20.45M -1.34B -21.23M -145M -57.23M -722M -53.72M -52.59M -2.28B 1.91M 1.74M 1.6M 1.45M 2.73M 179M 2.84M 19.34M 7.65M 96.48M 7.18M 7.03M 305M
Net Debt 3.68M 3.34M 3.08M 2.78M 5.25M 343M 5.45M 37.15M 14.69M 185M 13.79M 13.5M 586M -5.14M -4.66M -4.31M -3.89M -7.34M -480M -7.62M -51.91M -20.53M -259M -19.27M -18.87M -818M
Projected Income Statement - Annual - Petros Pharmaceuticals, Inc.
Logo Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Employees
3
Date Price Change Volume
17/11/26 US$0.003090 +3.00% 56,075
16/11/26 US$0.003000 +15.38% 19,830
13/11/26 US$0.002600 -7.64% 28,084
12/11/26 US$0.002815 -5.85% 6,165
11/11/26 US$0.002990 -5.83% 112,212

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Petros Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PTPI Stock